Autoimmune disorder with antiphospholipid antibodies causing arterial/venous thrombosis and pregnancy morbidity.
Also known as: APS, antiphospholipid syndrome, Hughes syndrome, lupus anticoagulant, anticardiolipin
Try two board-style Antiphospholipid Syndrome questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1HematologyMedium
A 35-year-old female with presumed antiphospholipid antibody syndrome (APS) based on a single positive anticardiolipin IgG has her second deep vein thrombosis (DVT) while on warfarin (INR 2.1). She has no known triple-positive APS. Which of the following is the most appropriate next step?
- AConfirm persistent APS antibody status
- BIncrease warfarin target INR to 4.5-5.0
- CSwitch to apixaban
- DAdd clopidogrel to current warfarin
Reveal answer & full explanation
Correct answer: A — Confirm persistent APS antibody status
- AConfirm persistent APS antibody status✓
- BIncrease warfarin target INR to 4.5-5.0
- CSwitch to apixaban
- DAdd clopidogrel to current warfarin
Why Confirm persistent APS antibody status is correct
- A single positive anticardiolipin IgG may be transient; antiphospholipid syndrome (APS) diagnosis requires two positive tests at least 12 weeks apart
- Before escalating anticoagulation, confirm persistent APS antibody positivity to ensure the diagnosis is truly established
- Also evaluate warfarin adherence and drug interactions that may have caused a low INR at the time of the thrombotic event
Why the others are wrong
- B) Increase warfarin target INR to 4.5-5.0 — for confirmed APS with recurrent thrombosis despite therapeutic warfarin, the appropriate INR target increase is to 3.0-4.0 (not 4.5-5.0), or adding low-dose aspirin 81 mg; an INR target of 4.5-5.0 carries excessive bleeding risk
- C) Switch to apixaban — direct oral anticoagulants (DOACs) are not recommended for triple-positive APS (the TRAPS trial showed rivaroxaban was inferior to warfarin); DOACs should be used with extreme caution in APS generally; apixaban may be considered after risk-benefit discussion only if the patient is truly single-positive and confirmed persistent
- D) Add clopidogrel to current warfarin — adding antiplatelet therapy to warfarin is not the standard approach for recurrent thrombosis in APS and increases bleeding risk without established benefit
Question 2HematologyMedium
A 38-year-old woman presents with recurrent deep vein thromboses (DVTs) and a spontaneous miscarriage at 14 weeks. She has livedo reticularis on exam. Labs show prolonged PTT that does not correct with mixing study. Anti-cardiolipin IgG and lupus anticoagulant are positive on two separate occasions 12 weeks apart. What is the most likely diagnosis?
- AHeparin-induced thrombocytopenia
- BFactor V Leiden
- CAntiphospholipid syndrome
- DProtein C deficiency
Reveal answer & full explanation
Correct answer: C — Antiphospholipid syndrome
- AHeparin-induced thrombocytopenia
- BFactor V Leiden
- CAntiphospholipid syndrome✓
- DProtein C deficiency
Why Antiphospholipid syndrome is correct
- Antiphospholipid syndrome (APS) requires clinical criteria (thrombosis or pregnancy morbidity) plus lab criteria (positive antiphospholipid antibodies on two occasions 12 weeks apart: lupus anticoagulant, anti-cardiolipin IgG/IgM, or anti-beta2-glycoprotein-I)
- This patient meets both: recurrent DVTs and spontaneous miscarriage at 14 weeks (clinical); positive anti-cardiolipin IgG and lupus anticoagulant on two separate occasions 12 weeks apart (lab)
- Prolonged PTT that does not correct with mixing (inhibitor pattern) is characteristic of lupus anticoagulant
Why the others are wrong
- A) Heparin-induced thrombocytopenia — HIT causes thrombocytopenia and thrombosis but requires prior heparin exposure; no heparin exposure is mentioned, and it does not explain the positive antiphospholipid antibodies or prolonged PTT inhibitor pattern
- B) Factor V Leiden — causes thrombophilia but does not explain prolonged PTT with inhibitor pattern, positive antiphospholipid antibodies, or pregnancy loss in this pattern
- D) Protein C deficiency — causes thrombophilia but would not cause a prolonged PTT that fails to correct with mixing, nor positive antiphospholipid antibodies
Additional high-yield points
- Treatment: warfarin (target INR 2-3 for venous thrombosis; INR 3-4 for recurrent or arterial thrombosis)
- Direct oral anticoagulants (DOACs) are not preferred in APS — rivaroxaban was inferior to warfarin in the RAPS trial
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Antiphospholipid Syndrome (APS) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Systemic lupus erythematosus (30-40% have APL antibodies; ~10-15% develop APS)
- Other autoimmune diseases — Sjögren syndrome, RA, systemic sclerosis
- Infections (transient antibodies) — syphilis, HIV, HCV
- Drug-induced — chlorpromazine, procainamide, hydralazine
- Family history of autoimmune disease
Pathophysiology
Pathogenic autoantibodies, principally anti-β2-glycoprotein-1, bind phospholipid-protein complexes on endothelium, platelets, and trophoblasts. Activation of complement, endothelial cells, and platelets shifts hemostatic balance toward thrombosis. In pregnancy, placental thrombosis and direct trophoblast injury cause miscarriage, IUGR, and preeclampsia.
Clinical presentation
Symptoms
- DVT, PE — most common manifestation
- Arterial thrombosis — stroke (especially in young patients), TIA, MI, limb ischemia
- Recurrent pregnancy loss (≥3 consecutive losses <10 weeks), late fetal loss ≥10 weeks, severe preeclampsia, IUGR
- Livedo reticularis — net-like purple skin discoloration
- Thrombocytopenia (mild-moderate)
- Cardiac valve thickening or vegetations (Libman-Sacks endocarditis)
- Cognitive dysfunction, migraine, transverse myelitis (less common)
Signs / physical exam
- Livedo reticularis or livedo racemosa
- Cutaneous ulcers, digital ischemia
- Cardiac murmur from valve involvement
- Focal neurological deficits
Classic findings
Triad in catastrophic APS: rapidly progressive multi-organ thrombosis (≥3 organs), histologic confirmation of small vessel occlusion, and persistent APL antibodies.
Differential diagnosis
- Hereditary thrombophilias — Family history, venous thrombosis predominant; negative APL antibodies on repeat testing
- Heparin-induced thrombocytopenia — Heparin exposure, platelet drop with thrombosis, positive anti-PF4 antibodies
- TTP / atypical HUS — Microangiopathic hemolytic anemia, schistocytes, low ADAMTS13 (TTP); responds to plasma exchange
- Catastrophic APS (CAPS) — Variant — multi-organ thrombosis within days, mortality >40%
- Malignancy-associated thrombosis — Occult cancer, often pancreatic, lung, GI
- Vasculitis — Constitutional symptoms, multi-system organ involvement, elevated inflammatory markers, characteristic biopsy
Diagnostic workup
Diagnostic criteria
Revised Sapporo (Sydney) criteria — requires ≥1 clinical criterion (vascular thrombosis or pregnancy morbidity) AND ≥1 laboratory criterion (LA, anti-cardiolipin, or anti-β2GP1) on two occasions at least 12 weeks apart. The 2023 ACR/EULAR criteria add weighted domain scoring and emphasize triple positivity.
Labs
- Three core antiphospholipid antibody tests, all measured on TWO occasions ≥12 weeks apart:
- - Lupus anticoagulant (LA) — coagulation-based assay (dRVVT, aPTT-based)
- - Anti-cardiolipin IgG and IgM (medium-high titer)
- - Anti-β2-glycoprotein-1 IgG and IgM
- CBC — assess for thrombocytopenia
- Coagulation studies — prolonged aPTT that does not correct with mixing study suggests lupus anticoagulant
- ANA, anti-dsDNA, complement to evaluate for SLE
- Direct Coombs (may coexist with AIHA)
Imaging
- Duplex US, CTPA, MRI brain as clinically indicated by symptoms
- Echocardiogram to evaluate for Libman-Sacks endocarditis
Treatment
First-line
- Acute thrombosis — therapeutic anticoagulation: unfractionated heparin or LMWH bridge to warfarin (INR 2-3)
- Long-term venous thrombosis — warfarin INR 2-3 indefinitely
- Long-term arterial thrombosis or recurrent venous thrombosis on warfarin — warfarin INR 3-4, or warfarin + low-dose aspirin
- DOACs (rivaroxaban, apixaban) are INFERIOR to warfarin in triple-positive APS — avoid
Obstetric APS (pregnancy)
- Prophylactic LMWH (enoxaparin 40 mg daily) PLUS low-dose aspirin (81 mg)
- Therapeutic LMWH if prior thrombosis
- Continue 6 weeks postpartum
- Avoid warfarin (teratogen 6-12 weeks; safe later); avoid DOACs in pregnancy
Catastrophic APS (CAPS)
- ICU-level care
- Triple therapy: anticoagulation (heparin) + high-dose glucocorticoids + plasma exchange and/or IVIG
- Rituximab or eculizumab for refractory cases
- Treat precipitating triggers (infection, surgery, drug withdrawal)
Asymptomatic antibody carriers
- Low-dose aspirin may be considered in high-risk profiles (triple-positive, SLE)
- Aggressive cardiovascular risk factor modification
- Avoid combined estrogen contraceptives
Second-line / adjunct
- Hydroxychloroquine — adjunctive, especially in SLE-associated APS
- Statins for vascular protection
- Rituximab or eculizumab for refractory/catastrophic disease
Complications
- Recurrent thrombosis despite anticoagulation
- Catastrophic APS (mortality 30-50%)
- Stroke and cumulative cognitive impairment
- Pregnancy loss, severe preeclampsia, HELLP
- Libman-Sacks endocarditis with embolic events
- Diffuse alveolar hemorrhage
- Adrenal hemorrhage and primary adrenal insufficiency
- Chronic kidney disease (APS nephropathy)
PANCE pearls
- Confirm any positive antiphospholipid test ≥12 weeks later — transient positivity occurs with infection.
- Triple-positive APS (LA + anti-cardiolipin + anti-β2GP1) confers highest thrombosis risk and warrants warfarin over DOACs (TRAPS trial).
- A prolonged aPTT that fails to correct on mixing study and corrects with added phospholipid suggests lupus anticoagulant.
- Warfarin INR target 2-3 for venous events; higher (or warfarin + ASA) for arterial events.
- Pregnant patients with APS should receive LMWH + aspirin, not warfarin (teratogen).
- Catastrophic APS is a life-threatening emergency — recognize and start triple therapy immediately.
References
- 2023 ACR/EULAR Criteria — Barbhaiya M et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol 2023.
- TRAPS trial — Pengo V et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132:1365-1371.
- Sapporo/Sydney criteria — Miyakis S et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006.